On April 28, 2021 Sanofi reported strong first quarter earnings, above market expectations, driven by growth across Dupixent and Vaccines.
For the first quarter, total sales volume decreased by 4.3% on a reported basis, to €8,591 million. The top line performance was negatively impacted by exchange rate movements, with a total negative effect of 6.7 percentage points. Excluding the impact of the currency movement, total sales increased by 2.4%, as strong growth across speciality care (+15.3%) and vaccines (+5.3%) more than offset sales declines across consumer health care (-7.3%) and general medicines (-3.8%). Click here to access the report